Cargando…

Tracheal cancer: a rare and deadly but potentially curable disease that also affects younger people

OBJECTIVES: The incidence of tracheal cancer is low, few clinicians get much experience and the awareness may be low. Recent data on the treatment and outcome are limited. The aim of the present study was to present updated, national data on the incidence, characteristics, treatment and outcome for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nilssen, Yngvar, Solberg, Steinar, Brustugun, Odd Terje, Møller, Bjørn, Sundset, Arve, Wahl, Sissel Gyrid Freim, Helland, Åslaug
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Thoracic
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329490/ https://www.ncbi.nlm.nih.gov/pubmed/37348858 http://dx.doi.org/10.1093/ejcts/ezad244

Ejemplares similares

Excessive Soft Tissue Reaction after Stereotactic Body Radiation Therapy in a Woman with Four Different Cancer Diagnoses
por: Turzer, Martin, et al.
Publicado: (2010)

Novel Molecular Tumor Cell Markers in Regional Lymph Nodes and Blood Samples from Patients Undergoing Surgery for Non-Small Cell Lung Cancer
por: Nordgård, Oddmund, et al.
Publicado: (2013)

Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC
por: Halvorsen, Ann Rita, et al.
Publicado: (2019)

The undifferentiated carcinoma that became a melanoma: Re-biopsy of a cancer of an unknown primary site: a case report
por: Røe, Oluf Dimitri, et al.
Publicado: (2017)

Stereotactic Body Radiation Therapy Is Effective and Safe in Patients with Early-Stage Non-Small Cell Lung Cancer with Low Performance Status and Severe Comorbidity
por: Turzer, Martin, et al.
Publicado: (2011)

Factors associated with emergency-related diagnosis, time to treatment and type of treatment in 5713 lung cancer patients
por: Nilssen, Yngvar, et al.
Publicado: (2021)

The immune microenvironment in non‐small cell lung cancer is predictive of prognosis after surgery
por: Öjlert, Åsa Kristina, et al.
Publicado: (2019)

Real-World Data on EGFR and ALK Testing and TKI Usage in Norway—A Nation-Wide Population Study
por: Eide, Inger Johanne Zwicky, et al.
Publicado: (2023)

Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
por: Rud, Ane Kongsgaard, et al.
Publicado: (2016)

Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2021)

Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
por: Haakensen, Vilde D., et al.
Publicado: (2020)

Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
por: Halvorsen, Ann Rita, et al.
Publicado: (2020)

NUT expression in primary lung tumours
por: Lund-Iversen, Marius, et al.
Publicado: (2015)

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors
por: McGowan, Marc, et al.
Publicado: (2017)

Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015–2016
por: Nilssen, Yngvar, et al.
Publicado: (2020)

The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma—differences in histological subtypes
por: Eide, Hanne A., et al.
Publicado: (2016)

Osteopontin is a prognostic biomarker in non-small cell lung cancer
por: Rud, Ane Kongsgaard, et al.
Publicado: (2013)

Diagnostic accuracy of circulating free DNA testing for the detection of KRAS mutations in non-small cell lung cancer: A systematic review and meta-analysis
por: Palmieri, Maria, et al.
Publicado: (2022)

The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung Carcinoma Revisited: A Norwegian Multicentre Study
por: Wahl, Sissel Gyrid Freim, et al.
Publicado: (2021)

Ectonucleotidase CD39 and Checkpoint Signalling Receptor Programmed Death 1 are Highly Elevated in Intratumoral Immune Cells in Non–small-cell Lung Cancer
por: Tøndell, Anders, et al.
Publicado: (2019)

Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016
por: Nilssen, Yngvar, et al.
Publicado: (2022)

Analysis of Intra-Tumoral Macrophages and T Cells in Non-Small Cell Lung Cancer (NSCLC) Indicates a Role for Immune Checkpoint and CD200-CD200R Interactions
por: Tøndell, Anders, et al.
Publicado: (2021)

Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2014)

Genome‐wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2015)

Rituximab efficiently depletes B cells in lung tumors and normal lung tissue
por: Joly-Battaglini, Albane, et al.
Publicado: (2016)

The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed
por: Frafjord, Astri, et al.
Publicado: (2021)

Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers
por: Berg, Janna, et al.
Publicado: (2021)

Retinoblastoma: a curable, rare and deadly blinding disease
por: Bowman, Richard
Publicado: (2018)

Identification of exercise‐regulated genes in mice exposed to cigarette smoke
por: Aakerøy, Lars, et al.
Publicado: (2022)

A NOTCH added to metabolomics
por: Brustugun, Odd Terje
Publicado: (2019)

Associations between detectable circulating tumor DNA and tumor glucose uptake measured by (18)F-FDG PET/CT in early-stage non-small cell lung cancer
por: Ottestad, Anine Larsen, et al.
Publicado: (2023)

Correction: Associations between detectable circulating tumor DNA and tumor glucose uptake measured by (18)F-FDG PET/CT in early-stage non-small cell lung cancer
por: Ottestad, Anine Larsen, et al.
Publicado: (2023)

Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer
por: Rud, Ane Kongsgaard, et al.
Publicado: (2012)

Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
por: Khadse, Anand, et al.
Publicado: (2022)

Asthma and asthma symptom control in relation to incidence of lung cancer in the HUNT study
por: Jiang, Lin, et al.
Publicado: (2021)

Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy
por: Wahl, Sissel Gyrid Freim, et al.
Publicado: (2021)

Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
por: Berg, Janna, et al.
Publicado: (2018)

Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
por: Eide, Inger Johanne Zwicky, et al.
Publicado: (2022)

Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
por: Eide, Hanne Astrid, et al.
Publicado: (2016)

Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 – 2020 - A population-based registry study from Norway
por: Børø, Siri, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e5kr5oqsbohsg54cq67pr54ocb